Cancer still represents a major public health and economic issue and its burden continues to grow globally. Over the last decade, the field of immunotherapy has undergone huge changes. Immunotherapy strategies, including the use of monoclonal antibodies, vaccines, tumor-infecting viruses, cytokines, adjuvants, and chimeric antigen receptor T cells (CARTs) that adjust the patient's immune system, have emerged as good treatment choices. Since only 20% of patients (20%) see lasting benefits from this mode of treatment, there is a critical need to turn our attention to other immune cells. Among them, the adoptive transfer of B cells engineered ex vivo has shown exciting results, with a reduction in tumor growth in several cancer models, often associated with antitumoral immune responses.
Aside from the advantages of their intrinsic properties, including antigen presentation, antibody secretion, and long-term persistence, at Creative Biolabs, B cells can be engineered to increase their therapeutic role, including engineering B Cells with costimulatory immune cell ligand (such as CD40L, CD70, OX40L, or 4-1BBL) or immuno-regulatory molecule secretion.
Fig.1 Workflow of B cell engineering. (Creative Biolabs)
A faster, cheaper, more accurate, and more efficient than other genome editing methods.
With flexible and precise positioning, and more potential of TALEN is still being tapped.
Homology-directed Repair (HDR)
A more accurate mechanism for double strand breaks repair and HDR can be used in many organisms.
Preserving genomic integrity and obviating the possibility of off-target genotoxicity.
Adeno-associated Virus (AAV) Vector
Carrying bulky and complex transgenes and sustaining robust and long-term expression.
Creative Biolabs has built a concentration of expertise and technical resources for engineering B cells with enhanced immuno-regulatory properties. Please do not hesitate to contact us if you are interested in our services.